Department of Pediatrics
Hong-Fen Guo has not added Biography.
If you are Hong-Fen Guo and would like to personalize this page please email our Author Liaison for assistance.
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.
The Journal of experimental medicine Aug, 1998 | Pubmed ID: 9705944
Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins.
Hybridoma and hybridomics Dec, 2002 | Pubmed ID: 12573107
Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
Hybridoma and hybridomics Aug, 2003 | Pubmed ID: 14511566
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia (New York, N.Y.) , 2004 | Pubmed ID: 15720811
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.
Cancer biotherapy & radiopharmaceuticals Oct, 2005 | Pubmed ID: 16248769
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
Cancer research Aug, 2009 | Pubmed ID: 19584290
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.
Molecular cancer therapeutics Apr, 2010 | Pubmed ID: 20371725
In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.
PloS one , 2013 | Pubmed ID: 23696816
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
Molecular cancer therapeutics Jul, 2014 | Pubmed ID: 24944121
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
The Journal of biological chemistry May, 2015 | Pubmed ID: 25851904
A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.
Stem cell research Sep, 2015 | Pubmed ID: 26342562
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.
The Journal of biological chemistry Dec, 2015 | Pubmed ID: 26487718
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
European journal of nuclear medicine and molecular imaging May, 2016 | Pubmed ID: 26596724
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Nov, 2017 | Pubmed ID: 28705917
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Molecular cancer therapeutics Oct, 2018 | Pubmed ID: 30082472
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Theranostics , 2018 | Pubmed ID: 30429889
An -Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.
Bioconjugate chemistry Mar, 2020 | Pubmed ID: 31891487
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.
Science translational medicine Mar, 2020 | Pubmed ID: 32161106
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2021 | Pubmed ID: 32958698
Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses.
Theranostics , 2020 | Pubmed ID: 33052220
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Journal for immunotherapy of cancer Nov, 2020 | Pubmed ID: 33239418
Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
Pediatric blood & cancer Jul, 2021 | Pubmed ID: 33844437
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Journal for immunotherapy of cancer May, 2021 | Pubmed ID: 34035113
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
Journal for immunotherapy of cancer Sep, 2021 | Pubmed ID: 34497115
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
Molecular cancer therapeutics Jan, 2022 | Pubmed ID: 34667111
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Journal for immunotherapy of cancer Mar, 2023 | Pubmed ID: 36990507
Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors.
Frontiers in oncology , 2023 | Pubmed ID: 37091153
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved
We use cookies to enhance your experience on our website.
By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.